Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies

被引：44

作者：

Haase, Volker H. ^{[1
,2
,3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA

[2] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA

[3] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA

来源：

EXPERIMENTAL CELL RESEARCH | 2017年 / 356卷 / 02期

关键词：

Hypoxia; Hypoxia-inducible factor; Anemia; Prolyl hydroxylase domain; Chronic kidney disease; Clinical trials; Oxygen; PROLYL HYDROXYLASE INHIBITOR; CHRONIC KIDNEY-DISEASE; INDUCIBLE FACTOR-I; PULMONARY-ARTERY PRESSURE; ROXADUSTAT FG-4592; EPOETIN-ALPHA; TRANSCRIPTIONAL ACTIVATION; ERYTHROPOIETIN PRODUCTION; IRON-DEFICIENCY; REGULATES HEPCIDIN;

D O I：

10.1016/j.yexcr.2017.05.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The oxygen-sensitive hypoxia-inducible factor (HIF) pathway plays a central role in the control of erythropoiesis and iron metabolism. The discovery of prolyl hydroxylase domain (PHD) proteins as key regulators of HIF activity has led to the development of inhibitory compounds that are now in phase 3 clinical development for the treatment of renal anemia, a condition that is commonly found in patients with advanced chronic kidney disease. This review provides a concise overview of clinical effects associated with pharmacologic PHD inhibition and was written in memory of Professor Lorenz Poellinger.

引用

页码：160 / 165

页数：6

共 102 条

[1] Multilineage embryonic hematopoiesis requires hypoxic ARNT activity [J].

Adelman, DM ;

Maltepe, E ;

Simon, MC .

GENES & DEVELOPMENT, 1999, 13 (19) :2478-2483

[2]

Akizawa T., 2015, NEPHROL DIAL TRAN S3, V30, piii8

[3] Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects [J].

Akizawa, Tadao ;

Tsubakihara, Yoshiharu ;

Nangaku, Masaomi ;

Endo, Yukihiro ;

Nakajima, Hiromu ;

Kohno, Tomoko ;

Imai, Yukiko ;

Kawase, Natsumi ;

Hara, Katsutoshi ;

Lepore, John ;

Cobitz, Alexander .

AMERICAN JOURNAL OF NEPHROLOGY, 2017, 45 (02) :127-135

[4] Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice [J].

Asada, Nariaki ;

Takase, Masayuki ;

Nakamura, Jin ;

Oguchi, Akiko ;

Asada, Misako ;

Suzuki, Norio ;

Yamarnura, Ken-ichi ;

Nagoshi, Narihito ;

Shibata, Shinsuke ;

Rao, Tata Nageswara ;

Fehling, Hans Joerg ;

Fukatsu, Atsushi ;

Minegishi, Naoko ;

Kita, Toru ;

Kimura, Takeshi ;

Okano, Hideyuki ;

Yamamoto, Masayuki ;

Yanagita, Motoko .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (10) :3981-3990

[5] Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats [J].

Barrett, Terrance D. ;

Palomino, Heather L. ;

Brondstetter, Theresa I. ;

Kanelakis, Kimon C. ;

Wu, Xiaodong ;

Yan, Wen ;

Merton, Katherine P. ;

Schoetens, Freddy ;

Ma, Jing Ying ;

Skaptason, Judy ;

Gao, Jingjin ;

Da-Thao Tran ;

Venkatesan, Hariharan ;

Rosen, Mark D. ;

Shankley, Nigel P. ;

Rabinowitz, Michael H. .

BRITISH JOURNAL OF PHARMACOLOGY, 2015, 172 (16) :4078-4088

[6] Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD [J].

Bernhardt, Wanja M. ;

Wiesener, Michael S. ;

Scigalla, Paul ;

Chou, James ;

Schmieder, Roland E. ;

Guenzler, Volkmar ;

Eckardt, Kai-Uwe .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (12) :2151-2156

[7] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].

Besarab, A ;

Bolton, WK ;

Browne, JK ;

Egrie, JC ;

Nissenson, AR ;

Okamoto, DM ;

Schwab, SJ ;

Goodkin, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590

[8] Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients [J].

Besarab, Anatole ;

Chernyayskaya, Elena ;

Motylev, Igor ;

Shutov, Evgeny ;

Kumbar, Lalathaksha M. ;

Gurevich, Konstantin ;

Chan, Daniel Tak Mao ;

Leong, Robert ;

Poole, Lona ;

Zhong, Ming ;

Saikali, Khalil G. ;

Franco, Marietta ;

Hemmerich, Stefan ;

Kin-Hung Peony Yu ;

Neff, Thomas B. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (04) :1225-1233

[9] Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients [J].

Besarab, Anatole ;

Provenzano, Robert ;

Hertel, Joachim ;

Zabaneh, Raja ;

Klaus, Stephen J. ;

Lee, Tyson ;

Leong, Robert ;

Hemmerich, Stefan ;

Yu, Kin-Hung Peony ;

Neff, Thomas B. .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (10) :1665-1673

[10] What Is So Bad About a Hemoglobin Level of 12 to 13 g/dL for Chronic Kidney Disease Patients Anyway? [J].

Besarab, Anatole ;

Frinak, Stanley ;

Yee, Jerry .

ADVANCES IN CHRONIC KIDNEY DISEASE, 2009, 16 (02) :131-142

← 1 2 3 4 5 6 7 8 9 10 →